Lapland reports surge in hepatitis B cases linked to drug use

Lapland has reported a significant increase in acute hepatitis B cases this year, with 20 confirmed so far. Typically, the region sees only a few infections annually. According to Markku Broas, the chief infectious disease physician at the Lapland welfare area, most cases are linked to the use of injected drugs. “Infections among injection drug users have spread from Rovaniemi to Meri-Lappi, where a few cases have been identified,” Broas explains.

Hepatitis B can be transmitted through unprotected sex and via blood, particularly through shared syringes and needles. The risk of infection can be reduced by using clean syringes and condoms. “At worst, an infection can lead to life-threatening liver failure,” Broas warns.

Nationwide, there have been 77 acute hepatitis B cases registered this year, according to the Infectious Disease Register of the Finnish Institute for Health and Welfare. The prevalence of hepatitis B has increased since 2021, with previous years averaging around ten cases annually. The highest number of acute hepatitis B cases was reported at the turn of the millennium, peaking in 1998 with 178 cases, after which figures fell sharply due to improved vaccination coverage.

Broas urges individuals who use intravenous drugs to get tested. “If they do not have an infection, injection drug users can receive the vaccine for free,” he emphasizes. Household members and partners of these users can also obtain the vaccine without charge. A series of three vaccinations offers lifelong protection against hepatitis B.

Individuals suspecting an acute hepatitis B infection can contact their local health center in any municipality in Lapland. Symptoms of acute hepatitis B infection include nausea, diarrhea, vomiting, abdominal pain, jaundice, and muscle and joint pain.